

### IFPMA pipeline update -Product Development for Vaccines Advisory Committee (PDVAC)

Paula Barbosa

Associate Director Vaccines Policy, IFPMA



### **Background**

Information based on **publicly available data**.

**Companies in scope**: AstraZeneca, Gilead, GSK, Johnson & Johnson, Merck & Co, Moderna, Novavax, Pfizer, Sanofi (*includes partnerships with non-IFPMA members* and between IFPMA members)

#### **Disease/pathogen groupings** used:

Respiratory	STI	Gastrointestinal	Parasitic	Bacterial	Viral
RSV	Chlamydia	ETEC	Malaria	Salmonella enterica Typhoid/paratyphoid	HSV
Influenza (next gen vaccines)	Syphilis	Shigella	Leishmania	Nontyphoidal salmonella disease	HPV
	HIV-1	Norovirus		Klebsiella pneumoniae	Cytomegalovirus
	Gonococcal vaccines (incl. MenB)	Rotavirus		Strep A/B	Hepatitis C virus
				tuberculosis	
				Staphylococcus aureus	
				ExPEC	


PDVAC agenda pathogens + global list of priority endemic pathogens for vaccine development




## IFPMA members are developing 64 influenza and RSV candidates, 13 of which are combination vaccines


Influenza/RSV candidates in clinical trials by IFPMA member companies

#### Standalone and combo influenza and RSV candidate pipeline for vaccines and prophylactic mAbs by IFPMA member companies





#### There are 13 combo vaccine in development by IFPMA members, most of which target COVID/influenza






## IFPMA members have 50 candidates targeting WHO priority pathogens in clinical trials


WHO priority pathogen candidates in clinical trials by IFPMA member companies

#### WHO priority pathogens candidate pipeline for vaccines and prophylactic mAbs by IFPMA member companies

Most candidates developed by IFPMA members are either in Phase I or II

The majority of candidates currently in trials are being investigated in STIs









# Thank you

### ifpma.org

in /company/ifpma



